Zenas BioPharma, Inc./$ZBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Ticker
$ZBIO
Sector
Primary listing
Employees
167
Headquarters
Website
ZBIO Metrics
BasicAdvanced
$1.2bn
-
-$8.82
-
-
Price and volume
Market cap
$1.2bn
52-week high
$44.60
52-week low
$8.91
Average daily volume
554k
Financial strength
Current ratio
11.938
Quick ratio
11.744
Long term debt to equity
79.145
Total debt to equity
79.454
Interest coverage (TTM)
-18.01%
Profitability
EBITDA (TTM)
-251.366
Effective tax rate (TTM)
-0.03%
Management effectiveness
Return on assets (TTM)
-29.06%
Return on equity (TTM)
-137.11%
Valuation
Price to book
3.48
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-3.673
Free cash flow yield (TTM)
-27.23%
Free cash flow per share (TTM)
-5.094
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
26.09%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs